M
Mark Rother
Researcher at Credit Valley Hospital
Publications - 10
Citations - 4112
Mark Rother is an academic researcher from Credit Valley Hospital. The author has contributed to research in topics: Panitumumab & KRAS. The author has an hindex of 6, co-authored 10 publications receiving 3714 citations. Previous affiliations of Mark Rother include University of Toronto.
Papers
More filters
Journal ArticleDOI
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
Jean-Yves Douillard,Kelly S. Oliner,Salvatore Siena,Josep Tabernero,Ronald Burkes,Mario Edmundo Barugel,Yves Humblet,György Bodoky,David Cunningham,Jacek Jassem,Fernando Rivera,Ilona Kocáková,Paul Ruff,Maria Blasinska-Morawiec,Martin Šmakal,Jean-Luc Canon,Mark Rother,Richard Thomas Williams,Alan Rong,Jeffrey Wiezorek,Roger Sidhu,Scott D. Patterson +21 more
TL;DR: Additional RAS mutations predicted a lack of response in patients who received panitumumab-FOLFOX4 treatment, which was consistent with the findings in patients with KRAS mutations in exon 2.
Journal ArticleDOI
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard,Salvatore Siena,Jim Cassidy,Josep Tabernero,Ronald Burkes,Mario Edmundo Barugel,Yves Humblet,György Bodoky,David Cunningham,Jacek Jassem,Fernando Rivera,Ilona Kocáková,Paul Ruff,Maria Blasinska-Morawiec,Martin Šmakal,Jean-Luc Canon,Mark Rother,Kelly S. Oliner,Michael S. Wolf,Jennifer Gansert +19 more
TL;DR: This study demonstrated that panitumumab-FOLFOX4 was well tolerated and significantly improved PFS in patients with WT KRAS tumors and underscores the importance of KRAS testing for patients with mCRC.
Journal ArticleDOI
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
Jean-Yves Douillard,Salvatore Siena,Jim Cassidy,Josep Tabernero,Ronald Burkes,Mario Edmundo Barugel,Yves Humblet,György Bodoky,David Cunningham,Jacek Jassem,Fernando Rivera,Ilona Kocáková,Paul Ruff,Maria Blasinska-Morawiec,Martin Šmakal,Jean-Luc Canon,Mark Rother,Kelly S. Oliner,Ying Tian,F. Xu,Roger Sidhu +20 more
TL;DR: In WT KRAS mCRC, PFS was improved, objective response was higher, and there was a trend toward improved OS with panitumumab-FOLFOX4, with significant improvement in OS observed in an updated analysis of survival.
Journal ArticleDOI
Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial analysis by epidermal growth factor receptor (EGFR) tumor staining.
Salvatore Siena,J. Tabernero,David Cunningham,P. Koralewski,Paul Ruff,Mark Rother,C. W. Johnson,A. Zhang,Jennifer Gansert,J.-Y. Douillard +9 more
TL;DR: This study evaluated the efficacy and safety of pmab + FOL FOX4 versus FOLFOX4 alone as first-line tx for mCRC by tumor KRAS status by analyzing analyses by EGFR staining.
Journal ArticleDOI
Adherence to surveillance guidelines after curative resection for stage II/III colorectal cancer.
Winson Y. Cheung,Gregory R. Pond,Mark Rother,Monika K. Krzyzanowska,Carol J. Swallow,James D. Brierley,Leonard Kaizer,Jeff Myers,Leena Hajra,Lillian L. Siu +9 more
TL;DR: Colorectal cancer surveillance revealed noticeable departures from ASCO guidelines, with the academic institution using a more intensive surveillance strategy with imaging studies than the community cancer center.